MAPT and ovarian cancer: For example, Tau overexpression observed in breast and ovarian cancer cells was correlated with a poor outcome [293,294,295], while downregulation of Tau in breast and ovarian cancer cell lines increased sensitivity to paclitaxel [293,295].